Achieve Life Sciences (ACHV) Expected to Announce Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is anticipated to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Achieve Life Sciences to post earnings of ($0.24) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Stock Down 0.2%

Shares of ACHV stock opened at $5.11 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.64 and a quick ratio of 6.64. The company has a market capitalization of $261.15 million, a price-to-earnings ratio of -3.50 and a beta of 1.58. The company’s fifty day moving average price is $3.51 and its 200-day moving average price is $3.06. Achieve Life Sciences has a one year low of $1.84 and a one year high of $5.78.

Analysts Set New Price Targets

A number of brokerages have commented on ACHV. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Wednesday, October 8th. HC Wainwright started coverage on shares of Achieve Life Sciences in a report on Thursday, August 21st. They set a “buy” rating and a $12.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Insiders Place Their Bets

In other news, CEO Richard Alistair Stewart sold 129,501 shares of the business’s stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $2.92, for a total value of $378,142.92. Following the completion of the sale, the chief executive officer owned 228,875 shares in the company, valued at approximately $668,315. The trade was a 36.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Cindy Jacobs sold 27,629 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $2.77, for a total transaction of $76,532.33. Following the completion of the sale, the chief marketing officer owned 115,585 shares of the company’s stock, valued at approximately $320,170.45. This represents a 19.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 381,972 shares of company stock worth $1,084,997. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Achieve Life Sciences by 39.9% during the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 9,617 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences during the 1st quarter worth approximately $32,000. Sender Co & Partners Inc. bought a new position in shares of Achieve Life Sciences during the 2nd quarter worth approximately $56,000. Shay Capital LLC raised its stake in shares of Achieve Life Sciences by 10.1% during the 2nd quarter. Shay Capital LLC now owns 292,647 shares of the biopharmaceutical company’s stock worth $661,000 after acquiring an additional 26,913 shares in the last quarter. Finally, Brevan Howard Capital Management LP bought a new position in shares of Achieve Life Sciences during the 2nd quarter worth approximately $145,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.